Skip to main content
Clinical Trials/NCT01667952
NCT01667952
Completed
N/A

Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness

Memorial Sloan Kettering Cancer Center1 site in 1 country1,068 target enrollmentAugust 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pediatric or Young Adult Cancer Survivors
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
1068
Locations
1
Primary Endpoint
establish a registry of DNA
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to establish a registry of survivors of cancer, tumor, or a related illness.

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
March 6, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • English speaking
  • A personal history of cancer tumor, or a related illness
  • Followed in the the Adult Long Term Follow Up Program, Pediatric Long Term Follow Up Program, or Lymphoma Service at MSKCC

Exclusion Criteria

  • Evidence of active progression of disease or recurrence
  • Neurocognitive deficits that impair ability to give informed consent.

Outcomes

Primary Outcomes

establish a registry of DNA

Time Frame: 4 years

For the purpose of facilitating future genetic laboratory investigations of late effects among of survivors of cancer, tumors, or a related illness. Patients in the ALTFU Program are followed for secondary malignant neoplasms and other adverse outcomes (so-called "late effects") including cardiomyopathy, pulmonary fibrosis, cardiac valvular pathology, osteoporosis, and others. The following data will be ascertained from each study participant: (1) family history information will be ascertained using the Family History Questionnaire (Appendix A); and (2) saliva or blood samples for genetic analysis.

Study Sites (1)

Loading locations...

Similar Trials